Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study

Compared to DPP4i, GLP-1 analogs may lower the risk of thromboembolic events and reduce all-cause mortality in RA patients with T2DM. Key Points • The study identified significantly reduced risks in both arterial and venous thrombosis in RA patients receiving GLP-1 analogs compared with DPP4i. • RA patients who received GLP-1 analogs had lower all-cause mortality compared to those receiving DPP4i. • These findings support potential dual benefit of GLP-1 analogs in reducing inflammation and thrombosis in RA patients with diabetes.